Stockreport

KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF Company achieved $35M in Q4 2025 and $49M in full-year 2025 unaudited EKTERLY revenues, with demand in Germany matching the U.S. launch trajectory. Key upside catalys [Read more]